AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • November 4th, 2021 • Prothena Corp Public LTD Co • Pharmaceutical preparations • California
This Amended and Restated Consulting Agreement (this “Agreement”) is effective as of July 15, 2020 (the “Effective Date”) and is made by and between Dennis J. Selkoe, M.D., an individual (“Consultant”), and Prothena Biosciences Inc, a Delaware corporation with offices at 331 Oyster Point Boulevard, South San Francisco, CA 94080, U.S.A. (“Prothena”). Consultant and Prothena may each be referred to individually herein as a “Party” and collectively as the “Parties”.
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both not material and the type of information that the registrant customarily and actually treats as private and confidential.License Agreement • November 4th, 2021 • Prothena Corp Public LTD Co • Pharmaceutical preparations • New York
This U.S. LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of July 30, 2021 (the “Effective Date”) by and between Prothena Biosciences Limited, an Irish limited company (“Prothena”) and Celgene Switzerland LLC, a Delaware limited liability company (“Celgene”). Celgene and Prothena are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both not material and the type of information that the registrant customarily and actually treats as private and...Share Purchase Agreement • November 4th, 2021 • Prothena Corp Public LTD Co • Pharmaceutical preparations • New York
This Share Purchase Agreement (as may be amended from time to time, this “Agreement”) is made and entered into as of July 8, 2021 by and among: Novo Nordisk A/S, an entity organized under the laws of Denmark (“Novo Nordisk”); Novo Nordisk Region Europe A/S, an entity organized under the laws of Denmark (“NNRE” and together with Novo Nordisk, “Buyer”); Prothena Biosciences Limited, a private company limited by shares incorporated under the laws of Ireland with registered number 460227 (“Seller”); and Prothena Corporation Plc, a public company limited by shares incorporated under the laws of Ireland with registered number 518146 (“Parent”). Parent is a party to this Agreement solely for purposes of Section 5.6 (Guaranty of Parent). Certain capitalized terms used in this Agreement are defined in Exhibit A.
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both not material and the type of information that the registrant customarily and actually treats as private and...Prothena Corp Public LTD Co • November 4th, 2021 • Pharmaceutical preparations • New York
This AMENDMENT NO. 2 (this “Amendment No. 2”) is made effective August 26, 2021 (“Amendment No. 2 Effective Date”) and hereby amends that certain LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (collectively, with all amendments thereto, the “Agreement”), dated December 11, 2013, by and between NEOTOPE BIOSCIENCES LIMITED (as of January 5, 2015, PROTHENA BIOSCIENCES LIMITED, “Prothena Ireland”) with respect to all rights and obligations under this Agreement outside of the United States, and PROTHENA BIOSCIENCES INC (“Prothena US”) with respect to all rights and obligations under this Agreement in the United States (Prothena US, together with Prothena Ireland, “Prothena”), on the one hand, and F. HOFFMANN-LA ROCHE LTD (“Roche Basel”) with respect to all rights and obligations under this Agreement outside of the United States, and HOFFMANN-LA ROCHE INC. (“Roche Nutley”) with respect to all rights and obligations under this Agreement in the United States (Roche Nutley, together with
